Start: Nov. 18, 2022
End: March 2024
Amyloid is a protein that forms plaques and is one of the hallmarks of Alzheimer's disease. During an amyloid PET brain scan, small amounts of a radioactive tracer are used to visualize amyloid in the brain. This study will test the safety and effectiveness of the radioactive tracer 18F-Fluselenamyl in people with normal cognition or early Alzheimer's. In the first stage of the study, participants with normal cognition will receive whole body PET-CT scans using different amounts of the 18F-Fluselenamyl tracer to determine dosage. In stage 2, all participants will complete cognitive tests and undergo PET imaging of the head and neck with the 18F-Fluselenamyl tracer. For comparison, an MRI scan and PET scan with another tracer, 11C-PIB, will also be collected. After 18 months, the imaging tests in stage 2 will be repeated in all participants. Throughout the study, all participants will be monitored for side effects.
Minimum Age: 18 Years
Maximum Age: N/A
Contact study personnel listed either under the general study contact or the location nearest you.
Washington University School of Medicine
Saint Louis, MO 63110
Lead: Washington University School of Medicine in St. Louis
Source: ClinicalTrials.gov ID: NCT05731440